Society guideline links: Bladder cancer

Introduction — This topic includes links to society and government-sponsored guidelines from selected countries and regions around the world. We will update these links periodically; newer versions of some guidelines may be available on each society's website. Some societies may require users to log in to access their guidelines.

The recommendations in the following guidelines may vary from those that appear in UpToDate topic reviews. Readers who are looking for UpToDate topic reviews should use the UpToDate search box to find the relevant content.

Links to related guidelines are provided separately. (See "Society guideline links: Screening for bladder cancer".)

International

●World Health Organization (WHO): Classification of tumours – Urinary and male genital tumours, 5th edition (2022)

•WHO: Classification of tumours of the urinary system and male genital organs – Part B: Prostate and urinary tract tumors (2022)

●Society for Immunotherapy of Cancer (SITC): Clinical practice guideline on immunotherapy for the treatment of urothelial cancer (2021)

●Société Internationale d'Urologie (SIU)-International Consultation on Urological Diseases (ICUD): Recommendations on bladder cancer – Systemic therapy for metastatic bladder cancer (2019)

●SIU-ICUD: A joint international consultation on bladder cancer (2017)

●Enhanced Recovery After Surgery (ERAS) Society: Guidelines for perioperative care after radical cystectomy for bladder cancer (2013)

Canada

●Canadian Urological Association (CUA): Guideline on the management of non-muscle-invasive bladder cancer (2021)

●Alberta Health Services (AHS): Clinical practice guideline on locally advanced/metastatic bladder cancer (2020)

●AHS: Clinical practice guideline on muscle-invasive bladder cancer (2020)

●CUA: Guideline on muscle-invasive bladder cancer (2019)

●CUA/Genitourinary Medical Oncologists of Canada (GUMOC): Consensus statement for management of unresectable locally advanced and metastatic urothelial carcinoma (2019)

●Cancer Care Ontario (CCO): Bladder cancer guideline –An endorsement of the 2017 American Urological Association (AUA)/American Society of Clinical Oncology (ASCO)/American Society for Radiation Oncology (ASTRO)/Society of Urologic Oncology (SUO) guideline for treatment of non-metastatic muscle-invasive bladder cancer (2018)

●AHS: Clinical practice guideline on nonmuscle invasive bladder cancer (2013)

United States

●National Cancer Institute (NCI): Bladder cancer treatment – Health professional version (updated 2023)

●NCI: Childhood bladder cancer treatment – Health professional version (updated 2022)

●American College of Radiology (ACR): ACR Appropriateness Criteria on post-treatment surveillance of bladder cancer, update (2021)

●American Urological Association (AUA)/American Society of Clinical Oncology (ASCO)/American Society for Radiation Oncology (ASTRO)/Society of Urologic Oncology (SUO): Guideline for treatment of non-metastatic muscle invasive bladder cancer (2017, amended 2020)

●AUA/SUO: Joint guideline for the diagnosis and treatment of non-muscle invasive bladder cancer (2016, amended 2020)

●ACR: ACR Appropriateness Criteria on pretreatment staging of muscle-invasive bladder cancer (2017)

●ASCO: Clinical practice guideline endorsement of the European Association of Urology (EAU) guideline on muscle-invasive and metastatic bladder cancer (2016)

Europe

●European Association of Urology (EAU): Guidelines on muscle-invasive and metastatic bladder cancer, update (2023)

●EAU: Guidelines on non-muscle-invasive bladder cancer (TAT1 and CIS), update (2023)

●European Society for Medical Oncology (ESMO): Bladder cancer – Clinical practice guideline for diagnosis, treatment, and follow-up (2021)

●Groupe Européen de Curiethérapie (GEC)-European Society for Radiotherapy and Oncology (ESTRO)/Advisory Committee on Radiation Oncology Practice (ACROP): Recommendations for performing bladder-sparing treatment with brachytherapy for muscle-invasive bladder carcinoma (2017)

●European Association of Urology Nurses (EAUN): Evidence-based guidelines for best practice in urological health care – Intravesical instillation with mitomycin C or bacillus Calmette-Guérin in non-muscle invasive bladder cancer (2015)

United Kingdom

●National Institute for Health and Care Excellence (NICE): Interventional procedures guidance on electrically stimulated intravesical chemotherapy for non-muscle-invasive bladder cancer (2019)

●NICE: Interventional procedures guidance on transurethral laser ablation for recurrent non-muscle-invasive bladder cancer (2019)

●NICE: Interventional procedures guidance on intravesical microwave hyperthermia and chemotherapy for non-muscle-invasive bladder cancer (2018)

●NICE: Guideline on bladder cancer – Diagnosis and management (2015)

●NICE: Quality standard on bladder cancer (2015)

Australia–New Zealand

●Royal Australian and New Zealand College of Radiologists (RANZCR): 2011 consensus guidelines for curative radiotherapy for urothelial carcinoma of the bladder (published 2012)

Japan

●[In English] Japanese Urological Association (JUA): Clinical practice guidelines for bladder cancer, 2019 edition by the revision working position paper (published 2020)

●[In Japanese] JUA: Bladder cancer practice guidelines (2019)